NRXP NRx Pharmaceuticals, Inc. Stock Quote

NRXP [NASD]

Index	-	P/E	-	EPS (ttm)	-8.08	Insider Own	59.40%	Shs Outstand	57.80M	Perf Week	0.74%
Market Cap	83.76M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	35.14M	Perf Month	-43.80%
Income	-348.90M	PEG	-	EPS next Q	-	Inst Own	14.20%	Short Float	7.34%	Perf Quarter	-54.82%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	248.19%	Short Ratio	4.28	Perf Half Y	-78.14%
Book/sh	0.36	P/B	3.78	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-93.44%
Cash/sh	0.45	P/C	3.03	EPS next 5Y	-	ROE	-	52W Range	1.15 - 48.80	Perf YTD	-71.55%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.21%	Beta	0.75
Dividend %	-	Quick Ratio	2.70	Sales past 5Y	-	Gross Margin	-	52W Low	18.26%	ATR	0.17
Employees	2	Current Ratio	2.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.00	Volatility	12.31% 11.32%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-31.70%	Profit Margin	-	Rel Volume	0.68	Prev Close	1.32
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 16 BMO	Payout	-	Avg Volume	603.20K	Price	1.36
Recom	-	SMA20	-16.90%	SMA50	-40.30%	SMA200	-78.99%	Volume	453,136	Change	3.03%

May-16-22 07:12AM	NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results PR Newswire
May-12-22 08:17AM	NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality PR Newswire
May-10-22 08:11AM	NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022 PR Newswire
Apr-21-22 08:48AM	NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress PR Newswire -13.15%
Apr-08-22 08:57AM	NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference PR Newswire -5.47%
Mar-31-22 08:17AM	NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results PR Newswire -14.04%
08:17AM	I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19 PR Newswire
Mar-28-22 03:17AM	NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022 PR Newswire
Mar-18-22 05:00AM	NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer PR Newswire
Mar-09-22 01:25PM	NRx Pharmaceuticals on search for new CEO American City Business Journals +26.44%
Mar-08-22 10:25PM	NRx Pharmaceuticals Announces Leadership Transition PR Newswire
Feb-21-22 07:21AM	How Much Of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Do Insiders Own? Simply Wall St.
Feb-15-22 08:32AM	NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment PR Newswire
Feb-11-22 08:01AM	NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife Covid-19 Investigational Vaccine GlobeNewswire -5.19%
Feb-02-22 07:06PM	NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules PR Newswire -8.98%
Jan-31-22 07:59AM	NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules PR Newswire
Jan-27-22 06:51AM	NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant PR Newswire -6.23%
Jan-26-22 06:51AM	NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge PR Newswire
Jan-20-22 08:28PM	KILL Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors Business Wire
Jan-18-22 06:48AM	NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments GlobeNewswire -8.26%
Jan-14-22 03:12PM	NRx Pharmaceuticals pursues Covid-19 vaccine as it continues work on treatment candidate American City Business Journals
02:34PM	NRx Responds to Reliefs Allegations of January 14, 2022 GlobeNewswire
Jan-12-22 05:48PM	NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics PR Newswire -5.00%
Jan-11-22 07:54AM	NRx Announces Planned Study Investigating BriLife Booster Vaccine Against Omicron Variant GlobeNewswire
Jan-07-22 05:50PM	NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife COVID-19 Vaccine GlobeNewswire -7.34%
12:29PM	Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M American City Business Journals
06:48AM	NRx Pharmaceuticals Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Jan-05-22 10:14AM	NRx Pharmaceuticals takes second shot at getting emergency use approval for Covid-19 treatment American City Business Journals
09:02AM	RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today? InvestorPlace
06:48AM	NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies PR Newswire
Jan-03-22 07:16AM	NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use PR Newswire
Dec-29-21 06:48AM	NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies PR Newswire +10.44%
Dec-19-21 06:38AM	Timothy Plan Israel Common Values Fund Buys Kornit Digital, Fattal Holdings (1998), Energean ... GuruFocus.com
Dec-15-21 06:48AM	NRx Pharmaceuticals Added to the Nasdaq® Biotech Index GlobeNewswire
Dec-14-21 06:48AM	NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 GlobeNewswire
Dec-09-21 09:21AM	NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials GlobeNewswire
Dec-06-21 09:07AM	NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions GlobeNewswire +8.27%
Nov-29-21 01:57PM	NRx Pharmaceuticals' stock jumps following new analysis of its potential Covid-19 drug American City Business Journals +20.00%
06:31AM	NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir GlobeNewswire
Nov-26-21 10:06AM	NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research GlobeNewswire +50.00%
Nov-16-21 05:56AM	NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results GlobeNewswire
Nov-12-21 11:46AM	NRx Pharmaceuticals Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference GlobeNewswire
Nov-11-21 07:54AM	NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing Information GlobeNewswire +6.27%
Nov-09-21 05:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP GlobeNewswire -5.06%
12:32PM	NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021 GlobeNewswire
10:00AM	Bronstein, Gewirtz & Grossman, LLC Alerts Shareholders of NRx Pharmaceuticals, Inc. (NRXP) Investigation ACCESSWIRE
Nov-08-21 12:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP Newsfile
11:00AM	Bronstein, Gewirtz & Grossman, LLC Alerts Shareholders of NRx Pharmaceuticals, Inc. (NRXP) Investigation ACCESSWIRE
Nov-05-21 05:45PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NRx Pharmaceuticals, Inc. (NRXP) Investigation ACCESSWIRE -25.45%
06:48AM	NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production PR Newswire
Nov-04-21 06:08PM	US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure PR Newswire -5.01%
Nov-02-21 11:04AM	NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 PR Newswire
Oct-14-21 06:48AM	Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure PR Newswire +26.17%
Oct-12-21 06:48AM	NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI (aviptadil) PR Newswire +61.06%
Sep-29-21 06:48AM	NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 PR Newswire
Sep-27-21 07:04AM	NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) PR Newswire +6.79%
Sep-08-21 07:48AM	NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
Aug-30-21 08:06AM	NRx Pharmaceuticals Announces New Finding from ZYESAMI (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 PR Newswire
Aug-26-21 06:48AM	NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies PR Newswire
Aug-25-21 09:43AM	What Is The Ownership Structure Like For NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)? Simply Wall St. -12.06%
Aug-24-21 06:48AM	NRx Pharmaceuticals Announces Closing of $30 Million Private Placement PR Newswire +6.53%
Aug-23-21 09:33AM	Participants in High Dose BriLife Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary PR Newswire +15.70%
Aug-19-21 09:17AM	NRx Pharmaceuticals Announces $30 Million Private Placement PR Newswire -15.21%
Aug-18-21 11:53AM	NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 PR Newswire +11.79%
Aug-16-21 09:32PM	NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update PR Newswire -6.37%
Aug-11-21 04:20PM	NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021 GlobeNewswire -10.41%
Aug-10-21 06:48AM	NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021 PR Newswire +13.04%
Aug-09-21 01:13PM	NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife Vaccine for Covid-19 in Nation of Georgia PR Newswire +14.99%
Aug-04-21 06:48AM	NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI (aviptadil) Inhaler for Respiratory Conditions PR Newswire -8.49%
06:48AM	MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere® Platform PR Newswire
Jul-27-21 11:34AM	NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI (aviptadil) in Nation of Georgia PR Newswire
Jul-22-21 06:48AM	NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval PR Newswire +62.71%
Jul-19-21 06:48AM	NRx Pharmaceuticals Presents Evidence ZYESAMI (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 PR Newswire +45.31%
Jul-12-21 11:18AM	NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine PR Newswire -16.16%
08:45AM	NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial PR Newswire
Jul-06-21 09:20AM	NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI (Aviptadil-acetate) Trial in the Nation of Georgia PR Newswire -8.04%
Jun-15-21 07:33AM	NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI (Aviptadil) Expanded Access Protocol PR Newswire
Jun-09-21 02:50PM	Fertility is not going to be affected in any way by COVID-19 vaccine: Doctor Yahoo Finance Video
Jun-08-21 02:03PM	U.S. response to COVID-19 has a greater list of failures than accomplishments: Expert Yahoo Finance Video -8.89%
Jun-07-21 01:45PM	U.S. should be very concerned as Delta variant spreads in Britain: Doctor Yahoo Finance Video
Jun-01-21 06:28AM	NRx Pharmaceuticals Announces Positive Results for ZYESAMI (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure PR Newswire
May-27-21 06:48AM	NRx Pharmaceuticals Names General H.R. McMaster to Company's Board of Directors PR Newswire
May-26-21 09:29AM	NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma PR Newswire -6.02%

NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Besthof Robert	Chief Comm. & Patient Officer	Sep 15	Sale	11.76	40,000	470,400	23,710	Nov 02 04:04 PM
Daigneault Alessandra	General Counsel & Secretary	Sep 02	Option Exercise	3.07	31,584	96,963	31,584	Nov 02 04:05 PM
McMaster Herbert Raymond	Director	Aug 26	Option Exercise	2.22	18,300	40,626	18,300	Nov 02 04:07 PM
Daigneault Alessandra	General Counsel & Secretary	Aug 23	Sale	13.11	33,715	442,004	0	Nov 02 04:05 PM
Daigneault Alessandra	General Counsel & Secretary	Aug 19	Option Exercise	3.07	27,395	84,103	33,715	Nov 02 04:05 PM
Besthof Robert	Chief Comm. & Patient Officer	Aug 16	Option Exercise	0.20	63,710	12,742	63,710	Nov 02 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience